Jing Shan¹, Catherine King^2,3, Harunor Rashid^3,4, Veysel Kayser^1,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070851 - 30 December 2025

Abstract Objectives: B-cell maturation antigen (BCMA)-targeted antibody–drug conjugates (ADCs) have emerged as promising therapies for relapsed/refractory multiple myeloma (RRMM), but the overall efficacy and safety profile is unclear. This study aimed to synthesize the available evidence on the safety and efficacy of BCMA-ADCs in development for RRMM. Methods: A systematic search was conducted using six bibliographic databases and ClinicalTrials.gov up to November 2024. Studies were eligible if they were human clinical trials or animal studies evaluating BCMA-ADCs and reported efficacy and safety outcomes. Data extraction and quality assessments were conducted using validated tools, including ROBINS-I… More >

Yi Tang^1,2,3,4,#, Minyi Situ^1,2,3,4,#, Zhiming Wu^1,2,3,4,#, Yanjun Wang^1,2,3,4,#, Xinpei Deng^1,2,3,4, Zhicheng Liu^1,2,3,4, Shengjie Guo^1,2,3,4, Qianghua Zhou^1,2,3,4,*, Gangjun Yuan^5,*, Xingliang Tan^1,2,3,4,*, Kai Yao^1,2,3,4,*

Oncology Research, Vol.33, No.12, pp. 3973-3989, 2025, DOI:10.32604/or.2025.066184 - 27 November 2025

Abstract Background: Current chemotherapy treatments, including the TIP (Taxol, Ifosfamide, Cisplatin) regimen, have shown limited effects but strong side effects in advanced Penile squamous cell carcinoma (PSCC) patients. Trophoblast cell-surface antigen-2 (TROP-2) is a novel target for antibody-drug conjugate (ADC) drugs and has been proven to be effective in several human cancers. This study aimed to explore the biological function and potential of the ADC target in PSCC cells. Methods: A total of 196 PSCC tumor tissue specimens and clinicopathological data were collected. TROP-2 expression was detected by IHC, and the correlation between TROP-2 expression and… More > Graphic Abstract

Xizhou Zhang^1,#, Zetao Zhang^1,#, Jianguang Lin², Jiarong Yi³, Xuxiazi Zou³, Jikun Feng³, Guangsheng Huang¹, Bingfeng Chen¹, Junxi Long¹, Fengjia Wu³, Feng Ye^3,*, Haoming Wu^1,*

Oncology Research, Vol.33, No.9, pp. 2529-2547, 2025, DOI:10.32604/or.2025.065029 - 28 August 2025

Abstract Background: Breast cancer remains a leading cause of morbidity and mortality among women worldwide, with significant geographic disparities in its impact. While human epidermal growth factor receptor 2 (HER2)-targeted therapies, such as trastuzumab, have improved outcomes for HER2-positive breast cancer, challenges like therapy resistance persist, highlighting the need for novel treatments. Recent developments in antibody-drug conjugates (ADCs), particularly disitamab vedotin (RC48), show promising efficacy in targeting both HER2-positive and HER2-low expression tumors, warranting further investigation through real-world studies to assess its broader clinical applicability. Method: This retrospective, multicenter observational study evaluated the real-world efficacy and… More >

LAZAR S. POPOVIC^1,2,*, GORANA MATOVINA-BRKO¹, MAJA POPOVIC^1,2, KEVIN PUNIE³, ANA CVETANOVIC^4,5, MATTEO LAMBERTINI^6,7

Oncology Research, Vol.31, No.3, pp. 221-238, 2023, DOI:10.32604/or.2023.028525 - 22 May 2023

Abstract Triple-negative breast cancer (TNBC) is a disease with often an aggressive course and a poor prognosis compared to other subtypes of breast cancer. TNBC accounts for approximately 10%–15% of all diagnosed breast cancer cases and represents a high unmet need in the field. Up to just a few years ago, chemotherapy was the only systemic treatment option for this subtype (1). To date, TNBC is considered a heterogeneous disease. One of the existing classifications is based on the analysis of mRNA expression in 587 TNBC cases, in which Lehman et al. proposed six subtypes of… More > Graphic Abstract